<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2016-9-4-59-63</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-60</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНО-ЛАБОРАТОРНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL AND LABORATORY STUDIES</subject></subj-group></article-categories><title-group><article-title>РОЛЬ ТРОМБОЦИТАРНОГО ФАКТОРА РОСТА В ПАТОБИОЛОГИИ ЭПИРЕТИНАЛЬНЫХ МЕМБРАН ПРИ ПРОЛИФЕРАТИВНОЙ ВИТРЕОРЕТИНОПАТИИ (ЭКСПЕРИМЕНТАЛЬНО-МОРФОЛОГИЧЕСКОЕ ИССЛЕДОВАНИЕ)</article-title><trans-title-group xml:lang="en"><trans-title>The role of platelet-derived growth factor in pathobiology of epiretinal membranes in proliferative vitreoretinopathy (an experimental morphological study)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хорошилова-Маслова</surname><given-names>И. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Khoroshilova-Maslova</surname><given-names>I. P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лепарская</surname><given-names>Н. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Leparskaya</surname><given-names>N. L.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Московский НИИ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz Research Institute of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>03</day><month>10</month><year>2018</year></pub-date><volume>9</volume><issue>4</issue><fpage>59</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хорошилова-Маслова И.П., Лепарская Н.Л., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Хорошилова-Маслова И.П., Лепарская Н.Л.</copyright-holder><copyright-holder xml:lang="en">Khoroshilova-Maslova I.P., Leparskaya N.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/60">https://roj.igb.ru/jour/article/view/60</self-uri><abstract><p>Пролиферативная витреоретинопатия (ПВР) представляет собой патологический процесс, в основе которого лежит пролиферация клеток ретинального пигментного эпителия (РПЭ) и глии на внутренней поверхности сетчатки с формированием эпиретинальных мембран. Патогенез заболевания остается недостаточно выясненным. Наиболее обоснованной является гипотеза о роли в патогенезе ПВР факторов роста/цитокинов, где тромбоцитарному фактору роста (PDGF) принадлежит ключевая роль. В статье приводится экспериментально-морфологическое изучение влияния PDGF на тканевые структуры глаза при его интравитреальном введении. Установлено, что РПЭ является основной мишенью воздействия PDGF. Выявлен дозозависимый характер воздействия. При дозах в 2000 мг/мл и 5000 мг/мл происходит диссоциация ретинальных эпителиальных клеток, их округление с формированием отростков, выход из пласта и миграция в окружающее пространство. При больших дозах (20000 мг/мл) наряду с обширной миграцией клеток и облысением мембраны Бруха происходит гибель фоторецепторных клеток сетчатки. Обсуждается механизм процессов миграции, связанный с воздействием PDGF на систему контрадгезивных протеинов РПЭ. Обоснована роль процессов миграции клеток РПЭ, индуцированных PDGF, в формировании начальной стадии ПВР // Российский офтальмологический журнал, 2016; 4: 59-63.</p></abstract><trans-abstract xml:lang="en"><p>Proliferative vitreoretinopathy (PVR) is a pathological process based on proliferation of retinal pigment epithelium (RPE) cells and glia on the interior surface of the retina accompanied by epiretinal membrane formation. The condition’s pathogenesis remains unclear. The best-founded hypothesis is that PVR pathogenesis involves growth factors and cytokines with the key role of platelet-derived growth factor (PDGF). The purpose of this work is an experimental morphologic study of changes in eye tissues after they were treated by recombinant PDGF administered intravitreally. Material and methods. 6 Chinchilla rabbits (12 eyes) were given intravitreal injections of 0.1 ml of PDGF through the flat part of the ciliary body. The concentrations were 2000 mg/ml (4 eyes), 5000 mg/ml (4 eyes), and 20000 mg/ml (4 eyes). Microscopic observation of the eyes, enucleated one month after the procedure was performed with a Leica microscopic system supplied with a digital camera with a x200-x600 magnification. Results. RPE was found to be the main target of PDGF. The impact was revealed to be dose-related. With doses of 2000 mg/ml and 5000 mg/ml retinal epithelial cells are dissociated, rounded, they form processes, fall out of the sheet and migrate to the surrounding area. With big doses (20000 mg/ml), death of photoreceptor cells in the retina occurs along with extensive migration of cells and Bruch's membrane denudement. The mechanism underlying migration processes, associated with the influence of PDGF on the system of counter-adhesive proteins is discussed. Conclusion. The role of migration of RPE cells induced by PDGF in the formation of the early stage of PVR was demonstrated // Russian Ophthalmological Journal, 2016; 4: 59-63. doi: 10.21516/2072-0076-2016-9-4-59-63.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Пролиферативная витреоретинопатия</kwd><kwd>ретинальный пигментный эпителий</kwd><kwd>факторы роста</kwd><kwd>цитокины</kwd><kwd>тромбоцитарый фактор роста</kwd><kwd>proliferative vitreoretinopathy</kwd><kwd>retinal pigment epithelium</kwd><kwd>growth factors</kwd><kwd>cytokines</kwd><kwd>platelet-derived growth factor</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Charteris D.G., Sertini C.S., Levis G.P., Fisher S.K. Proliferative vitreoretinopathy - developments in adjunctive treatment and retinal pathology. Eye. 2002; 16: 369-74.</mixed-citation><mixed-citation xml:lang="en">Charteris D.G., Sertini C.S., Levis G.P., Fisher S.K. Proliferative vitreoretinopathy - developments in adjunctive treatment and retinal pathology. Eye. 2002; 16: 369-74.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Moysidis S., Thanos A., Vavvas D. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Hindawy Publishing Corporation. Mediators of inflammation. 2012; Article ID 815937: 11.</mixed-citation><mixed-citation xml:lang="en">Moysidis S., Thanos A., Vavvas D. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Hindawy Publishing Corporation. Mediators of inflammation. 2012; Article ID 815937: 11.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Morescalchi F., Duse S., Gambicorti E., et al. Proliferative vitreoretinopathy after eye injuries: an over expression of growth factors and cytokines leading to a retinal keloid. Hindawy Publishing Corporation. Mediators of inflammation. 2013. Article JD 269787: 12.</mixed-citation><mixed-citation xml:lang="en">Morescalchi F., Duse S., Gambicorti E., et al. Proliferative vitreoretinopathy after eye injuries: an over expression of growth factors and cytokines leading to a retinal keloid. Hindawy Publishing Corporation. Mediators of inflammation. 2013. Article JD 269787: 12.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sadaka A., Giuliary G. Proliferative vitreoretinopathy current and emerging treatments. Clinical Ophthalmology. 2012; 6: 1325-33.</mixed-citation><mixed-citation xml:lang="en">Sadaka A., Giuliary G. Proliferative vitreoretinopathy current and emerging treatments. Clinical Ophthalmology. 2012; 6: 1325-33.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lei H., Rheaume M., Kaziauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Research. 2010; 90(3): 376-81.</mixed-citation><mixed-citation xml:lang="en">Lei H., Rheaume M., Kaziauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Research. 2010; 90(3): 376-81.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Li R., Maiminishkis A., Wang F., Miller Sh. PDGF-C and PDGF-D induced proliferation/migration of human RPE is abolished by inflammatory cytokines. Invest Ophthalmol Vis Sci. 2007; 48(12): 5722-32.</mixed-citation><mixed-citation xml:lang="en">Li R., Maiminishkis A., Wang F., Miller Sh. PDGF-C and PDGF-D induced proliferation/migration of human RPE is abolished by inflammatory cytokines. Invest Ophthalmol Vis Sci. 2007; 48(12): 5722-32.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Leschey K.H., Hines J., Singer J., Hockett S., Compochiaro P. Inhibition of Growth Factor effects in retinal pigment epithelial cells. Investigative Ophthalmology. 1991; 32(6): 1770-8.</mixed-citation><mixed-citation xml:lang="en">Leschey K.H., Hines J., Singer J., Hockett S., Compochiaro P. Inhibition of Growth Factor effects in retinal pigment epithelial cells. Investigative Ophthalmology. 1991; 32(6): 1770-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Leschey K.H., Hockett S., Singer J., Compochiaro P. Growth factor responsiveness of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1990; 31(5): 839-46.</mixed-citation><mixed-citation xml:lang="en">Leschey K.H., Hockett S., Singer J., Compochiaro P. Growth factor responsiveness of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1990; 31(5): 839-46.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pennock S., Rheaume M., Mukai Sh., Kaziauskas A. A novel strategy to develop therapeutic approaching to prevent proliferative vitreoretinopathy. American Journal of Pathology. 2011; 179(6): 2931-40.</mixed-citation><mixed-citation xml:lang="en">Pennock S., Rheaume M., Mukai Sh., Kaziauskas A. A novel strategy to develop therapeutic approaching to prevent proliferative vitreoretinopathy. American Journal of Pathology. 2011; 179(6): 2931-40.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hiscott P., Hogan S., Heathcote L., et al. Pathobiology of epiretinal and subretinal membranes: possible roles for the matricellular proteins thrombospondin and osteonectin (SPAKC). Eye. 2002; 16: 393-403.</mixed-citation><mixed-citation xml:lang="en">Hiscott P., Hogan S., Heathcote L., et al. Pathobiology of epiretinal and subretinal membranes: possible roles for the matricellular proteins thrombospondin and osteonectin (SPAKC). Eye. 2002; 16: 393-403.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
